WO2026046393 - PREPARATION AND USE OF INDOLE DERIVATIVE
National phase entry is expected:
Publication Number
WO/2026/046393
Publication Date
05.03.2026
International Application No.
PCT/CN2025/118197
International Filing Date
01.09.2025
Title **
[English]
PREPARATION AND USE OF INDOLE DERIVATIVE
[French]
PRÉPARATION ET UTILISATION D'UN DÉRIVÉ D'INDOLE
[Chinese]
吲哚类衍生物的制备及其应用
Applicants **
SHANDONG SIMCERE ZAIMING BIOPHARMACEUTICAL CO., LTD.
Inventors
CHEN, Xiang
ZHU, Wei
HUAN, Xiang
LI, Wenqiang
ZHANG, Jun
LI, Zhengtao
Priority Data
202411222341.3
02.09.2024
CN
202411460752.6
18.10.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2108 | |
| EPO | Filing, Examination, Granting | 15598 | |
| Japan | Filing, Examination, Granting | 2370 | |
| South Korea | Filing, Examination, Granting | 2629 | |
| USA | Filing, Examination, Granting | 5140 |
Total:
27,845
Contact Us
Abstract[English]
The present disclosure relates to a RAS inhibitor compound represented by formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof in preparation of drugs for preventing or treating RAS-mediated diseases.[French]
La présente invention concerne un composé inhibiteur de RAS représenté par la formule (I) ou un stéréoisomère de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique le contenant, et son utilisation dans la préparation de médicaments pour la prévention ou le traitement de maladies médiées par RAS.[Chinese]
本公开涉及式(I)所示RAS抑制剂化合物或其立体异构体或其药学上可接受的盐、含有它们的药物组合物、以及其在制备预防或治疗RAS介导的疾病中的用途。